Cytokinetics’ CK-274 Appears To Upstage BMS’s Newly Acquired Mavacamten
Phase III Trial To Start By Year’s End
The REDWOOD-HCM study showed early, sustained efficacy and no serious adverse events with a drug Cytokinetics designed to be superior to mavacamten, a drug it spun out via BMS-acquired MyoKardia.
